Physician profile
Barbara E Denuyl
NPI 1235186966
$747.80
in general payments reported to CMS, 2019-2025
13 companies · $142 in 2025
The $142 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $15.52 · 2022: $108 · 2023: $182 · 2024: $177 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $186.82 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $118.26 | 2025 | |
| Merck Sharp & Dohme LLC | $90.84 | 2019-2024 | Vaxelis, Gardasil, M-M-R II |
| Corium, LLC | $55.08 | 2022-2023 | Azstarys |
| Sanofi Pasteur INC. | $52.74 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $45.21 | 2019 | |
| Glaxosmithkline, LLC. | $41.68 | 2019-2024 | Menveo, Bexsero, Rotarix |
| Seqirus USA INC | $41.15 | 2022-2023 | Flucelvax Quadrivalent |
| Cranial Technologies, INC | $36.05 | 2023-2024 | Doc Band |
| Collegium Pharmaceutical, INC. | $23.35 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $23.14 | 2023 | Flumist Quadrivalent |
| Sobi, INC | $17.11 | 2019 | |
| Kaleo, INC. | $16.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Denuyl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.